| Note |
New from Lilly. Parkotil. The On-Time-Extended. New Chances for Chron's Parkinson. Parkotil. The first orale D1 and D2 Dopamine agonist. Chance 1: Parkotil a dopamine with novel activity profile. Stimulates D1 and D2 dopamine receptors. Acts similar to a natural dopamine. Has a long half-life. Has a high degree of potency. Chance 2: Parkotil significantly prolonged the IN-time and reduces the OFF-time. Chance 3: Parkotil significantly reduced the daily dose of levodopa and extends the dosing intervals. Chance 4: Parkotil is often more effective in non-responding patients on bromocriptine. The meaning for your patients: Parkotil improves daily activities such as walking, dressing, speaking, eating, daily hygiene. Parkotil the first oral D1 and D2 Dopamine Antagonist. |
